CDTX - Cidara Therapeutics Inc
IEX Last Trade
11.9
-1.050 -8.824%
Share volume: 40,634
Last Updated: Fri 30 Aug 2024 08:59:04 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$12.95
-1.05
-8.11%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-03 | 2023-03-23 | 2023-05-11 | 2023-08-03 | 2023-11-02 | 2024-04-22 | 2024-05-15 | |
| Assets | |||||||||
| Total Assets | 39.524 M | 66.858 M | 47.593 M | 81.736 M | 67.986 M | 63.468 M | 67.030 M | 52.716 M | |
| Current Assets | 36.546 M | 63.899 M | 45.094 M | 79.488 M | 62.240 M | 57.704 M | 60.855 M | 46.834 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 1.954 M | 2.467 M | 6.097 M | 7.269 M | |
| Other Current Assets | 6.706 M | 5.779 M | 6.530 M | 5.686 M | 4.373 M | 3.712 M | 2.734 M | 3.266 M | |
| Short Term Investments | 6.706 M | 5.779 M | 6.530 M | 5.686 M | 4.373 M | 3.712 M | 2.734 M | 3.266 M | |
| Total Receivables | 4.833 M | 5.042 M | 5.833 M | 25.826 M | 5.483 M | 2.855 M | 16.246 M | 7.281 M | |
| Current Cash | 24.637 M | 53.078 M | 32.731 M | 47.976 M | 50.430 M | 48.670 M | 35.778 M | 29.018 M | |
| Total Non-current Assets | 2.978 M | 2.959 M | 2.499 M | 2.248 M | 5.746 M | 5.764 M | 6.175 M | 5.882 M | |
| Property Plant Equipment | 201.000 K | 173.000 K | 222.000 K | 270.000 K | 297.000 K | 580.000 K | 557.000 K | 534.000 K | |
| Other Assets | 2.777 M | 2.786 M | 2.277 M | 1.978 M | 5.449 M | 5.184 M | 5.618 M | 5.348 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 39.524 M | 66.858 M | 47.593 M | 81.736 M | 67.986 M | 63.468 M | 67.030 M | 52.716 M | |
| Total liabilities | 47.485 M | 57.791 M | 50.497 M | 54.899 M | 52.572 M | 55.430 M | 75.240 M | 70.496 M | |
| Total current liabilities | 31.455 M | 33.049 M | 29.972 M | 35.663 M | 31.420 M | 35.620 M | 67.418 M | 65.425 M | |
| Accounts Payable | 3.091 M | 4.244 M | 1.447 M | 3.980 M | 1.899 M | 3.661 M | 3.772 M | 5.055 M | |
| Other liabilities | 15.351 M | 24.398 M | 20.525 M | 19.236 M | 17.551 M | 16.504 M | 4.245 M | 1.888 M | |
| Current long term debt | 1.603 M | 1.277 M | 1.317 M | 1.001 M | 942.000 K | 1.051 M | 1.300 M | 1.464 M | |
| Long term debt | 679.000 K | 344.000 K | 0.000 | 0.000 | 3.601 M | 3.306 M | 3.577 M | 3.183 M | |
| Other liabilities | 15.351 M | 24.398 M | 20.525 M | 19.236 M | 17.551 M | 16.504 M | 4.245 M | 1.888 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -7.961 M | 9.067 M | -2.904 M | 26.837 M | 15.414 M | 8.038 M | -8.210 M | -17.780 M | |
| Common stock | 69.134 M | 70.218 M | 71.941 M | 78.640 M | 90.116 M | 90.287 M | 4.533 M | 226.889 K | |
| Retained earnings | -408.567 M | -393.589 M | -406.966 M | -403.757 M | -416.114 M | -424.286 M | -441.431 M | -451.757 M |